Literature DB >> 30651633

ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis.

Ying Guo1,2, Yuan Zhou3, Shohei Yamatomo1,2, Hui Yang1,2, Peng Zhang1,2, Shi Chen1,2, Stephen D Nimer1,2, Zhizhuang Joe Zhao4, Mingjiang Xu1,2, Jie Bai5,6, Feng-Chun Yang7,8.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30651633     DOI： 10.1038/s41375-018-0347-y

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  1 in total

1.  Letter: Bone-marrow responses in polycythemia vera.

Authors:  J F Prchal; A A Axelrad
Journal:  N Engl J Med       Date:  1974-06-13       Impact factor: 91.245
  1 in total
  8 in total

1.  Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations.

Authors:  Jiajia Yuan; Junzhe Song; Chao Chen; Xue Lv; Jie Bai; Jing Yang; Yuan Zhou
Journal:  Invest New Drugs       Date:  2022-08-31       Impact factor: 3.651

Review 2.  The role of driver mutations in myeloproliferative neoplasms: insights from mouse models.

Authors:  Kotaro Shide
Journal:  Int J Hematol       Date:  2019-12-21       Impact factor: 2.490

Review 3.  Accelerated Phase of Myeloproliferative Neoplasms.

Authors:  Omar A Shahin; Helen T Chifotides; Prithviraj Bose; Lucia Masarova; Srdan Verstovsek
Journal:  Acta Haematol       Date:  2021-04-21       Impact factor: 2.195

Review 4.  Epigenetic Dysregulation of Myeloproliferative Neoplasms.

Authors:  Andrew Dunbar; Young Park; Ross Levine
Journal:  Hematol Oncol Clin North Am       Date:  2021-02-05       Impact factor: 3.722

5.  Ruxolitinib Reduces Oxidative Stress in Patients With Primary Myelofibrosis: A Multicenter Study.

Authors:  Mahmut B Koyuncu; Mustafa Ilgan; Hakan Basir; Anil Tombak; Mehmet Ali Ucar; Tolga Koseci; Aydan Akdeniz; Eyup N Tiftik; Özcan Erel
Journal:  Cureus       Date:  2022-01-04

6.  Rapid progression of myelofibrosis in polycythemia vera patient carrying SRSF2 c.284C>A p.(Pro95His) and unique ASXL1 splice site c.1720-2A>G variant.

Authors:  Zuzanna Kanduła; Renata Kroll-Balcerzak; Krzysztof Lewandowski
Journal:  J Clin Lab Anal       Date:  2022-04-18       Impact factor: 3.124

Review 7.  ASXL1/2 mutations and myeloid malignancies.

Authors:  Edward A Medina; Caroline R Delma; Feng-Chun Yang
Journal:  J Hematol Oncol       Date:  2022-09-06       Impact factor: 23.168

Review 8.  The Molecular Genetics of Myeloproliferative Neoplasms.

Authors:  Anna E Marneth; Ann Mullally
Journal:  Cold Spring Harb Perspect Med       Date:  2020-02-03       Impact factor: 6.915
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.